Skip to content

US · BBLGW · BIOTECHNOLOGY

Bone Biologics Corporation (BBLGW) intrinsic value and stock valuation

$4.06as of 2026-09-18 · Mkt cap 819.1K

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bone Biologics Corporation DCF and intrinsic value

InvestorsCraft values BBLGW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BBLGW’s statements →

Bone Biologics Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burlington, MA, US bonebiologics.com

How the business is doing

Fiscal 2025–2008, USD

Revenue
$0.00
20252008
Net income
-$-13.34B
20252008
Free cash flow
-$-24.33B
20252008
Total equity
$0.00
20252009

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2008, USD
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-3.23T-$-4.22T-$-9.43T-$-3.67T-$-1.1T
Net income-$-3.11T-$-4.11T-$-8.95T-$-1.48T-$-1.61T
EPSd-$-2.65M-$-2.71M-$-34.01M-$-31.15M-$-37.35M
Operating cash flow-$-2.69T-$-4.12T-$-9.56T-$-3.57T-$-1.23T
Capital expenditure$0.00-$-5M$0.00$0.00$0.00
Free cash flow-$-2.69T-$-4.12T-$-9.56T-$-3.57T-$-1.23T
Total assets$5.8T$3.86T$3.74T$8.5T$6.68T
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.33T-$-3.33T-$-3.03T-$-7.54T-$-6.68T
Total equity$5.38T$3.48T$2.91T$5.95T$6.58T
Cash and short-term investments$5.33T$3.33T$3.03T$7.54T$6.68T
Income statement
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$1.06T$2.13T$6.91T$1.58T$82B
Selling, general and administrative expenses$2.17T$2.09T$2.52T$2.09T$1.02T
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.23T$4.22T$9.43T$3.67T$1.1T
Cost and expenses$3.23T$4.22T$9.43T$3.67T$1.1T
Interest income$122B$55.7B$1.87B$0.00$805.1M
Interest expense$0.00$0.00$0.00$731.7B$805.1B
Depreciation and amortization$0.00$4.22T$9.43T$0.00$0.00
Ebitda-$-3.11T$107.2B$479.6B-$-752.91B-$-805.58B
Operating income-$-3.23T-$-4.22T-$-9.43T-$-3.67T-$-1.1T
Total other income/expenses, net$126B$106.7B$479.6B$2.18T-$-507.61B
Income before tax-$-3.11T-$-4.11T-$-8.95T-$-1.48T-$-1.61T
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.11T-$-4.11T-$-8.95T-$-1.48T-$-1.61T
Weighted average shares outstanding$1.17T$1.52T$263.1B$47.6B$43B
Weighted average diluted shares outstanding$1.17T$1.52T$263.1B$47.7B$43.1B
Balance sheet
FYFYFYFYFY
Cash and short-term investments$5.33T$3.33T$3.03T$7.54T$6.68T
Net receivables$9.9B$0.00$328.8B$579.9B$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.8T$3.86T$3.74T$8.5T$6.68T
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$0.00
Total assets$5.8T$3.86T$3.74T$8.5T$6.68T
Accounts payable$417.9B$373B$360.7B$104.8B$99.9B
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$783.7B$0.00
Total current liabilities$418.6B$377.7B$831.4B$2.55T$99.9B
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$418.6B$377.7B$831.4B$2.55T$99.9B
Common stock$1.8B$2.95B$534M$15.3B$10.4B
Retained earnings-$-88.13T-$-85.02T-$-80.91T-$-71.96T-$-70.48T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.38T$3.48T$2.91T$5.95T$6.58T
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.33T-$-3.33T-$-3.03T-$-7.54T-$-6.68T
Cash flow statement
FYFYFYFYFY
Net income-$-3.11T-$-4.11T-$-8.95T-$-1.48T-$-1.61T
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$256.4B$188.8B$152.6B$266.6B$207B
Change in working capital$165.5B-$-150.25B$132.9B-$-168.37B-$-320.49B
Accounts receivable-$-9.9B$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$91B$89.8B$255.9B$788.6B-$-365.49B
Net cash provided by operating activities-$-2.69T-$-4.12T-$-9.56T-$-3.57T-$-1.23T
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$4.7T$2.62T$5.04T$4.43T$6.86T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-3.21T$0.00$0.00$0.00
Net cash used for financing activities$4.7T$4.42T$5.04T$4.43T$7.9T
Net change in cash$2.01T$298.6B-$-4.51T$862.9B$6.68T
Cash at end of period$5.33T$3.33T$3.03T$7.54T$6.68T
Operating cash flow-$-2.69T-$-4.12T-$-9.56T-$-3.57T-$-1.23T
Capital expenditure$0.00-$-5M$0.00$0.00$0.00
Free cash flow-$-2.69T-$-4.12T-$-9.56T-$-3.57T-$-1.23T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bone Biologics Corporation

        Bone Biologics Corporation is a medical device firm dedicated to revolutionizing bone regeneration, particularly within spinal fusion procedures. The company's primary innovation is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein. This bio-engineered protein offers precise, targeted control over new bone formation. Currently, Bone Biologics is advancing the NELL-1/DBX Fusion Device, specifically engineered for spinal fusion applications in skeletally mature patients suffering from degenerative disc disease, focusing on single-level fusions from L4 to S1. Beyond spinal applications, the versatility of its foundational technology promises to deliver improved outcomes across various surgical disciplines, including general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Underpinning its development, the company holds a licensing agreement with the UCLA Technology Development Group to further develop and commercialize NELL-1 for spinal fusion. Established in 2004, Bone Biologics Corporation is headquartered in Burlington, Massachusetts.

        CEO
        Jeffrey Frelick
        Employees
        2
        Beta
        0.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Bone Biologics Corporation (BBLGW)?

        InvestorsCraft does not currently publish an intrinsic value for BBLGW. How the IC value is calculated.

        Is BBLGW undervalued?

        InvestorsCraft does not publish an undervaluation signal for BBLGW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.